Thulium Laser and Growth Factors for Androgenetic Alopecia
ConditionAndrogenetic Alopecia (AGA)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversitätsklinikum Hamburg-Eppendorf
About this trial
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected.
Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity.
Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
Eligibility criteria
Qualifiers
Men and women aged 18 and over
Good general health, no relevant previous illnesses
Presence of an AGA
Cognitive ability and willingness to give consent (informed consent)
Disqualifiers
Age < 18 years
Pregnant or breastfeeding women
Scarring alopecia, alopecia due to dermatoses (e.g. lichen ruber, lupus erythemodes,...), alopecia due to chemical or physical noxae, and other non-AGAs
Significant scarring of the region to be treated
Trial design
Treatments tested in this trial
- Thulium laser + growth factor serum + LED
- Thulium laser + growth factor serum
- Thulium laser
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov